Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72744
Title:
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Authors:
Weigert, Oliver; Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Hiddemann, Wolfgang; Dreyling, Martin
Abstract:
Radioimmunotherapy (RIT) with Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) combines the tumor targeting attributes of a monoclonal antibody against the CD20 antigen and the pure beta-radiation of 90Y. High efficacy and a favorable safety profile have been demonstrated in Phase II and III clinical trials enrolling patients with CD20+ B-cell non-Hodgkin lymphoma (B-NHL). On the basis of these results, 90Y-ibritumomab tiuxetan was approved in the United States for the treatment of patients with follicular lymphoma (FL) or transformed B-NHL. In the European Union its use was restricted to FL, refractory to or relapsed after rituximab. There are a number of important clinical trials currently evaluating 90Y-ibritumomab tiuxetan in other subtypes of lymphoma such as diffuse large-cell and mantle-cell lymphoma, as consolidation therapy or as part of myeloablative regimens. In light of the constantly increasing clinical experience with RIT, clinicians face the challenge of how to best integrate this promising new treatment option into existing established treatment algorithms. By incorporating the most recent data in this rapidly developing field, this review article focuses on current recommendations for the use of 90Y-ibritumomab tiuxetan in patients with malignant lymphoma, outlines future perspectives, and provides practical recommendations for patient management.
Affiliation:
Department of Internal Medicine III, University of Munich, Munich, Germany.
Citation:
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. 2006, 107 (4):686-95 Cancer
Journal:
Cancer
Issue Date:
15-Aug-2006
URI:
http://hdl.handle.net/10541/72744
DOI:
10.1002/cncr.22066
PubMed ID:
16826593
Type:
Article
Language:
en
ISSN:
0008-543X
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWeigert, Oliver-
dc.contributor.authorIllidge, Timothy M-
dc.contributor.authorHiddemann, Wolfgang-
dc.contributor.authorDreyling, Martin-
dc.date.accessioned2009-07-07T11:55:14Z-
dc.date.available2009-07-07T11:55:14Z-
dc.date.issued2006-08-15-
dc.identifier.citationRecommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. 2006, 107 (4):686-95 Canceren
dc.identifier.issn0008-543X-
dc.identifier.pmid16826593-
dc.identifier.doi10.1002/cncr.22066-
dc.identifier.urihttp://hdl.handle.net/10541/72744-
dc.description.abstractRadioimmunotherapy (RIT) with Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) combines the tumor targeting attributes of a monoclonal antibody against the CD20 antigen and the pure beta-radiation of 90Y. High efficacy and a favorable safety profile have been demonstrated in Phase II and III clinical trials enrolling patients with CD20+ B-cell non-Hodgkin lymphoma (B-NHL). On the basis of these results, 90Y-ibritumomab tiuxetan was approved in the United States for the treatment of patients with follicular lymphoma (FL) or transformed B-NHL. In the European Union its use was restricted to FL, refractory to or relapsed after rituximab. There are a number of important clinical trials currently evaluating 90Y-ibritumomab tiuxetan in other subtypes of lymphoma such as diffuse large-cell and mantle-cell lymphoma, as consolidation therapy or as part of myeloablative regimens. In light of the constantly increasing clinical experience with RIT, clinicians face the challenge of how to best integrate this promising new treatment option into existing established treatment algorithms. By incorporating the most recent data in this rapidly developing field, this review article focuses on current recommendations for the use of 90Y-ibritumomab tiuxetan in patients with malignant lymphoma, outlines future perspectives, and provides practical recommendations for patient management.en
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHumans-
dc.subject.meshLymphoma-
dc.subject.meshPractice Guidelines as Topic-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshYttrium Radioisotopes-
dc.titleRecommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Internal Medicine III, University of Munich, Munich, Germany.en
dc.identifier.journalCanceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.